All references FDA: Concerns with unapproved GLP-1 drugs used for weight loss NEJM (2023): Retatrutide Phase 2 trial in obesity Eli Lilly: Phase 2 retatrutide results published in NEJM Eli Lilly (Dec 2025): Phase 3 TRIUMPH-4 topline results announcement ClinicalTrials.gov: NCT05882045 (TRIUMPH-3) Drugs.com: Retatrutide status & timeline Lilly Trials: TRIUMPH-3 summary page
Science 274 , 16721677 (1996) Sinha, D., Chen, M.-H., Ghosh, S.K.: Bayesian analysis and model selection for interval-censored survival data
The commonly explored processes include but are not limited to a transport process mediated by the transferrin receptor (TfR), insulin receptor, members of the LDL receptor family for receptors-mediated processes [8] and by the glucose transporter (GLUTs) and amino acid transporter for carrier (transporter)-mediated processes [18]
Chronische ontstekingen en aandoeningen: bij diabetes, auto-immuunziekten, infecties, laaggradige ontstekingen en langdurige leverproblemen wordt glutathion continu ingezet om schade te beperken
7,4- ( , Lee et al., 2016)
Effects on Nerve Tissue IGF-1 has significant neuroprotective effects, enhancing the survival and function of neurons
